Zynerba Pharmaceuticals (NASDAQ:ZYNE) released its earnings results on Monday. The company reported ($0.44) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.21, MarketWatch Earnings reports.
NASDAQ ZYNE opened at $4.86 on Tuesday. The firm has a market cap of $85.67 million, a P/E ratio of -1.96 and a beta of 4.98. Zynerba Pharmaceuticals has a fifty-two week low of $2.75 and a fifty-two week high of $12.50.
Several equities analysts recently weighed in on ZYNE shares. Zacks Investment Research upgraded Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.00 target price on the stock in a research report on Saturday, November 17th. HC Wainwright set a $23.00 target price on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, November 13th. Cantor Fitzgerald reiterated a “buy” rating and set a $11.00 target price on shares of Zynerba Pharmaceuticals in a research report on Thursday, March 7th. Finally, ValuEngine upgraded Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 5th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $13.38.
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
Recommended Story: Why is Cost of Capital Important?
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.